Anuh Pharma (506260) investor relations material

Executive summary

• Q1 FY27 saw operating revenue rise 3.93% year-over-year to ₹193.81 crore, with profit growth outpacing revenue due to a shift toward higher-value products in regulated markets.

• Margins improved at all levels, driven by a richer product mix, disciplined cost control, and better asset throughput.

• USFDA and EU GMP clearances have positioned the regulated-market pipeline as the main growth engine.

• Board approved unaudited financial results for the quarter ended 30th June 2026, with review by statutory auditors and audit committee.

• Promoter group members withdrew requests for reclassification to public category and will remain promoters.

Financial highlights

• Operating profit increased 39.50% year-over-year to ₹38.15 crore, with a margin of 19.68%.

• EBITDA rose 41.56% year-over-year to ₹19.36 crore, margin at 9.99% versus 7.34% last year.

• Profit before tax grew 54.55% year-over-year to ₹16.93 crore; PAT up 37.63% to ₹11.42 crore.

• EPS increased 37.63% year-over-year to ₹1.14.

• Revenue from operations for Q1 FY27 was ₹19,381.04 lakhs, up from ₹18,647.94 lakhs year-over-year.

Outlook and guidance

• Anticipates steady annual growth of 15-20% driven by volume expansion and high-value regulated market growth.

• Focus on process innovation, cost optimization, and strategic export market diversification to mitigate currency risk.

• Continued investments in compliance, operational efficiency, and capacity enhancement.

• No explicit forward-looking guidance provided, but continued focus on core bulk drug and chemicals segment.